Related Experiment Videos
Immune response to plasmid DNA encoding HPV16-L1 protein
1Institute of Immunopathology, Xi'an Medical University, Xi'an 710061, China. sgtwyl@pub.xa-online.sn.cn
Chinese Medical Journal
|January 5, 2002
Summary
Recombinant plasmid DNA encoding human papillomavirus type 16-L1 (HPV16-L1) induced a detectable immune response in mice. This DNA vaccine approach shows promise for developing future HPV16 prophylactic vaccines.
Area of Science:
- Molecular Biology
- Immunology
- Vaccine Development
Background:
- Human papillomavirus (HPV) is a major cause of cervical cancer.
- The HPV16-L1 protein is a key target for prophylactic HPV vaccines.
Purpose of the Study:
- To evaluate the immunogenicity of a recombinant plasmid DNA encoding HPV16-L1 in mice.
- To assess the potential of DNA-based HPV vaccines.
Main Methods:
- Constructed a eukaryotic expression plasmid (pcDNA-L1) containing the HPV16-L1 gene.
- Transfected Cos-7 cells and immunized BALB/c mice via intramuscular injection.
- Assessed L1 protein expression and anti-HPV16-L1 antibody production using immunospot and immunocytochemistry.
Main Results:
- Confirmed HPV16-L1 protein expression in transfected cells, localized to the nucleus.
- Detected specific anti-HPV16-L1 antibodies in immunized mice starting 28 days post-initial immunization.
- Antibody response persisted for at least 41 days.
Conclusions:
- Successfully constructed an HPV16-L1 eukaryotic expression plasmid.
- Demonstrated that the plasmid DNA can elicit a humoral immune response in mice.
- The findings support the development of DNA-based HPV16 prophylactic vaccines.